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OBJECTIVES We sought to evaluate the association between cholesteryl ester transfer protein (CETP)
genotypes and the risk of future cardiovascular mortality in patients with coronary artery
disease (CAD).
BACKGROUND Polymorphisms of the CETP gene influence CETP activity and high-density lipoprotein
(HDL) cholesterol concentration and might affect the long-term prognosis and response to
statin therapy in patients with CAD.
METHODS We used serum samples and deoxyribonucleic acid collected at baseline from a prospective
cohort of 1,211 patients with CAD prospectively followed up (median follow-up of 4.1 years),
82 of whom experienced a fatal cardiovascular event. The CETP/C-629A and I405V
polymorphisms, CETP activity, and HDL cholesterol were determined.
RESULTS Patients carrying the 629A allele had significantly lower CETP activity and higher HDL
cholesterol levels. There was a significant association between this polymorphism and the risk
of future cardiovascular death. Mortality decreased from 10.8% in CC homozygotes to 4.6%
in CA heterozygotes and 4.0% in AA homozygotes (p  0.0001). This association was
independent of potential confounders, particularly HDL cholesterol and CETP activity
levels. The clinical benefit of statin therapy was restricted to CC homozygotes, in whom
cardiovascular mortality was divided by half (p  0.01 for treatment  genotype interaction).
Similar trends were observed with the CETP/I405V polymorphism, but these effects seemed
to be mainly the consequence of linkage disequilibrium with the CETP/C-629A polymor-
phism.
CONCLUSIONS In patients with CAD, the CETP/629A allele had a strong protective effect on future
mortality from cardiovascular causes, independent of its role on HDL cholesterol and CETP
activity levels. Additionally, this common polymorphism appeared to predict which patients
with CAD will experience a survival benefit from statin therapy. (J Am Coll Cardiol 2003;
41:1983–9) © 2003 by the American College of Cardiology Foundation
The inverse relationship between serum high-density li-
poprotein (HDL) cholesterol and ischemic heart disease has
increasingly been recognized in numerous clinical and epi-
demiologic studies (1). Cholesteryl ester transfer protein
See page 1990
(CETP) distributes cholesteryl esters and triglycerides be-
tween lipoproteins and is a key enzyme in reverse cholesterol
transport (RCT) and HDL metabolism (2,3). However,
whether CETP acts in a pro- or anti-atherogenic fashion
still remains controversial (4–6).
A major deficiency of CETP activity due to rare genetic
mutations has been reported to be associated with an
increased prevalence of coronary artery disease (CAD) in
Japanese men, despite high levels of HDL cholesterol (7). A
common polymorphism of the CETP gene located in intron
1 (TaqIB) has consistently been shown to influence CETP
activity and HDL cholesterol levels (8–12). However, this
polymorphism is unlikely to be functional by itself and
rather reflects the effect of one or several functional variants
of the CETP gene (13). In particular, the TaqIB polymor-
phism was found to be in nearly complete association with
the CETP/C-629A polymorphism located in the promoter
(13), which was further shown to influence gene expression
and CETP activity (14).
Patients with low plasma HDL cholesterol receive a
clinical benefit from statin therapy (15). Because of the
strong impact of CETP gene variations on HDL choles-
terol, it might be hypothesized that CETP polymorphisms
modulate the effect of statin therapy on HDL cholesterol
and possibly on CAD risk. Supporting this hypothesis, it
was recently shown that the TaqIB polymorphism was
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associated with different effects of pravastatin treatment on
progression of coronary atherosclerosis (16).
In light of the previous findings, the present study was
primarily aimed at investigating whether CETP gene poly-
morphisms influence CETP activity, HDL cholesterol con-
centrations, and long-term prognosis in a large, prospective
cohort of German patients with CAD. A secondary hypoth-
esis investigated was whether CETP polymorphisms might
modulate the clinical benefits of statin therapy on future
CAD events. Among the different polymorphisms that were
previously described in the CETP gene (14), we selected for
this study the functional promoter CETP/C-629A polymor-
phism and the exonic CETP/I405V polymorphism, because
they had been previously shown to have the strongest
influence on CETP activity and HDL cholesterol (14).
METHODS
Study participants. A detailed description of the design of
the AtheroGene Study has been outlined previously (17).
Briefly, between November 1996 and June 2000, 1,303
patients who underwent coronary angiography at the De-
partment of Medicine II of the Johannes Gutenberg-
University Mainz or the Bundeswehrzentralkrankenhaus
Koblenz and who had at least one stenosis30% diagnosed
in a major coronary artery were enrolled in a cardiovascular
registry. Of the patients, 910 (70%) presented with stable
angina and 393 (30%) presented with an acute coronary
syndrome; in the latter group, 336 had unstable angina by
the Braunwald classification (class B or C) and 57 had an
acute myocardial infarction (MI) within the previous 48 h.
The present study was based on 1,211 patients (92.9%) who
were genotyped for both the CETP/C-629A and CETP/
I405V polymorphisms. Missing genotype information was
due to technical difficulties or a lack of deoxyribonucleic
acid.
Evaluation of end points. A total of 1,206 (99.6%) of
1,211 patients were followed up during a median period of
4.1 years (maximum 5.2 years). Patients either presented at
our clinic (87.2%) or a telephone interview was performed
by trained medical staff. Follow-up information was ob-
tained on death from cardiovascular causes, including fatal
MI, sudden cardiac death, and death from vascular causes (n
 82); death from causes not related to heart disease (n 
25); nonfatal MI (n  50); and nonfatal stroke (n  31).
Information on the cause of death or clinical events was
obtained from hospital or general practitioner charts. Statin
prescription status was obtained by a questionnaire at study
enrollment and was available for all study subjects. A total of
411 patients (34%) had been receiving treatment with one of
six different statins at study entry (immediately before
coronary angiography) and as discharge medication and
continued to take this medication at the time of follow-up
(atorvastatin 24.7%, cerivastatin 19.3%, pravastatin 18.4%,
simvastatin 17.3%, lovastatin 17.1%, or fluvastatin 3.2%).
All patients who received statin therapy as discharge med-
ication but did not continue to take it during follow-up were
identified as “dropouts” and considered in the group of “no
statin medication.” Use of statin therapy at the end of
follow-up was verified by a questionnaire and general
practitioner charts.
Study participants had a German nationality. The study
was approved by the local ethics committee. Participation
was voluntary, and each subject gave written, informed
consent.
Laboratory analysis. Blood was drawn under standardized
conditions, samples were stored at 80°C until analysis.
Lipid serum levels (total cholesterol, HDL cholesterol,
low-density lipoprotein [LDL] cholesterol, and triglycer-
ides) were determined immediately, and apolipoprotein A-I
and B-100 concentrations by an immunoturbidometric
assay (Tina-quant, Roche Diagnostics, Mannheim, Germa-
ny). C-reactive protein was measured by a highly sensitive,
latex particle-enhanced immunoassay (Roche Diagnostics).
The CETP activity was measured by a fluorescence method
(Roar Biomedical, Inc., New York, New York). All infor-
mation for genotyping can be obtained at our Internet site
(http://www.genecanvas.org).
Statistical analysis. Hardy-Weinberg equilibrium was
tested by the chi-square test with one degree of freedom.
Linkage disequilibrium between the two polymorphisms
was estimated by log-linear analysis (18) and was expressed
by the standardized coefficient D’. The association between
CETP genotypes and lipid levels was tested by analysis of
variance, comparing the mean values of lipids across geno-
types. For the association of prospective outcome with
genotype, a first combined cardiovascular end point, includ-
ing death from cardiovascular causes, nonfatal MI, and
nonfatal stroke, was considered. Because the association
appeared mainly driven by cardiovascular mortality, further
survival analyses focused on cardiovascular mortality and
data on patients who died of other causes were censored at
the time of death. The cumulative survival plot in relation to
CETP genotypes was estimated by the Kaplan-Meier
method with the use of the log-rank test. Hazard risk ratios
(HRRs) of future cardiovascular mortality, according to
CETP polymorphisms, were estimated by Cox regression
analysis. The interaction between the CETP/C-629A poly-
morphism and statin treatment on cardiovascular mortality
was tested by introducing a corresponding interaction term
in the Cox model. In survival analyses, the p value associated
Abbreviations and Acronyms
CAD  coronary artery disease
CETP  cholesteryl ester transfer protein
CI  confidence interval
HDL  high-density lipoprotein
HRR  hazard risk ratio
LDL  low-density lipoprotein
MI  myocardial infarction
RCT  reverse cholesterol transport
VLDL  very-low-density lipoprotein
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with genotype was obtained assuming a co-dominant allele
effect (genotype entered as an ordinal variable 0, 1, or 2), as
this genetic model appeared to fit well with the data. A
value of p  0.05 was considered to be significant. All
computations were carried out with SPSS, version 10.07
(SPSS Inc., Chicago, Illinois).
RESULTS
Characteristics of study population according to clinical
outcome. The mean age of the entire study population was
61.5 10.2 years; 76.1% were male patients. Table 1 shows
the patients’ characteristics according to clinical outcome.
CETP genotypes and intermediate lipid phenotypes.
The genotype distribution for CETP/C-629A significantly
deviated from the Hardy-Weinberg expectations (p 
0.008) due to a deficit of homozygotes. Because the cohort
was composed of patients with CAD, this result might be
explained by a lower frequency than that expected of the AA
genotype, as already reported in patients with CAD (13).
To check this hypothesis, we compared the genotype
frequencies of this cohort with those of a control sample of
574 German individuals recruited at the same time as the
cohort (19). The frequencies of the CC, CA, and AA
genotypes were 30.8%, 51.7%, and 17.4%, respectively, in
the control sample (p  0.20 for the Hardy-Weinberg
equilibrium test), compared with 36.9%, 50.6%, and 12.5%,
respectively, in the CAD cohort (p  0.004 for the
genotype difference between groups), confirming the lower
frequency of the AA genotype in this CAD cohort. The
genotype distribution for CETP/I405V was compatible with
the Hardy-Weinberg expectations (p  0.21) and did not
differ from that of the control group (p  0.78). Both
polymorphisms were in moderate linkage disequilibrium
Table 1. Baseline Characteristics of Patients
Characteristics
Patients Without CV
Death (n  1,124)
Patients With CV
Death (n  82) p Value
Age (yrs) 61.1  10.2 67.6  7.6 0.0001
Body mass index (kg/m2) 27.1  3.7 26.5  4.5 0.2
Male (%) 76.0 75.3 0.9
History
Hypertension (%) 70.6 81.5 0.04
Diabetes mellitus (%) 14.6 29.6 0.0001
Family history of CAD (%) 39.9 32.1 0.2
Smoking status
Current smokers (%) 27.5 35.7 0.3
Ever smokers (%) 55.4 59.1 0.6
Lipid status
Total cholesterol (mg/dl) 221  45 219  51 0.7
LDL cholesterol (mg/dl) 142  40 142  42 0.9
HDL cholesterol (mg/dl) 48  15 44  14 0.02
Triglycerides (mg/dl) 141 (102/196) 154 (113/210) 0.2
Apolipoprotein A-I (g/l) 1.31  0.24 1.25  0.27 0.04
Apolipoprotein B-100 (g/l) 1.21  0.29 1.22  0.30 0.6
CETP activity (pmol/l/h) 37.4  21.0 40.6  18.2 0.3
Previous MI (%) 48.9 58.0 0.1
Acute coronary syndrome (%) 32.8 23.5 0.08
Ejection fraction* (%) 63.2  14.3 49.9  18.7 0.0001
Number of affected coronary arteries (%) 0.4
1 vessel 26.6 23.5
2 vessels 29.4 24.7
3 vessels 44.0 51.9
Cardiac medications (%)
Beta-blockers 60.1 39.5 0.0001
1 drug for CHF† 58.9 87.7 0.0001
1 anti-anginal drug‡ 62.7 69.1 0.3
Statins 34.5 27.2 0.2
Invasive treatment
PTCA (%) 21.9 30.9 0.06
CABG (%) 47.5 35.8 0.05
hs-CRP (mg/dl) 0.4 (0.2/1.2) 0.8 (0.2/2.6) 0.008
*Ejection fraction was determined in 1,020 patients. †Drugs for congestive heart failure (CHF) included diuretics, angiotensin-
converting enzyme inhibitors, digitalis drugs, and diuretics. ‡Anti-anginal drugs included calcium channel inhibitors and
long-acting nitroglycerin. Categorical variables are presented as percentage of patients; continuous variables are presented as
mean values  SD or median values (25th/75th interquartiles) for skewed distributions. To convert cholesterol values to
millimoles per liter, multiply by 0.02586. To convert triglycerides values to millimoles per liter, multiply by 0.01129.
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CETP  cholesteryl ester transfer protein;
CV  cardiovascular; HDL and LDL  high- and low-density lipoprotein, respectively; hs-CRP  high sensitive C-reactive
protein; MI  myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty.
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(D’  0.26, p  0.001), with the 629A and 405V alleles
being preferentially associated.
The two polymorphisms influenced HDL cholesterol and
CETP activity levels, with the 629A and the 405V alleles
being associated with both an increase in HDL cholesterol
and a decrease in CETP activity in a co-dominant fashion
(Table 2).
CETP genotypes and clinical outcome. A significant
association was found between the CETP/C-629A polymor-
phism and the combined cardiovascular end point (Table 3).
Carriers of the 629A allele had a reduced risk compared
with CC homozygotes (p  0.032). This association was
mainly driven by cardiovascular mortality (p  0.0001),
with no effect observed for nonfatal MI or stroke (Table 3).
There was also a borderline association of this polymor-
phism with noncardiovascular mortality (p  0.045), but
the number of deaths was small. The association between
the CETP/I405V polymorphism and the combined cardio-
vascular end point did not reach statistical significance.
However, as for the CETP/C-629A polymorphism, there
was a significant association with cardiovascular mortality
(Table 3). Further survival analyses focused then on cardio-
vascular mortality. The relationship between genotypes and
cardiovascular mortality was illustrated in the Cox survival
plot (Fig. 1).
Multivariate analyses. To explore whether CETP geno-
types predicted future fatal cardiovascular events indepen-
dent of most significant clinical and therapeutic confound-
ers, several models were fitted (Table 4). Despite the effect
of the CETP/C-629A polymorphism on HDL cholesterol
and CETP activity, inclusion of these variables in different
models hardly modified the association of genotype with
clinical outcome. Similar results were observed with the
CETP/I405V genotype, although the association was
weaker and lost significance after adjustment for CETP
activity (Table 4). In a model including both polymor-
phisms, only the CETP/C-629A polymorphism remained
significantly associated with clinical outcome. Assuming a
co-dominant allele effect on risk, the HRR associated with
the 629A allele was 0.51 (95% confidence interval [CI]
0.35 to 0.75; p  0.001), and the HRR associated with the
405V allele was 0.71 (95% CI 0.48 to 1.06; p  0.10) in a
model including the two polymorphisms simultaneously.
The protective effect of the 629A allele on cardiovascular
mortality was of a similar magnitude in stable patients
(HRR 0.48, 95% CI 0.31 to 0.73; p  0.001) and in patients
with acute coronary syndrome (HRR 0.53, 95% CI 0.25 to
1.12; p  0.10) (p  0.85 for homogeneity of the effect).
Benefit of statin therapy according to CETP/C-629A
genotype. A significant interaction between the CETP/C-
629A genotype and statin treatment on cardiovascular mor-
tality was observed. Actually, the benefit of statin therapy
was restricted to patients homozygous for the 629C allele.
In these patients, mortality was divided by half in those
Table 2. Baseline CETP Activity and Lipid Concentrations According to CETP Genotypes
Variable CETP/C-629A CETP/I405V
CC (n  447) CA (n  613) AA (n  151) p Value II (n  606) IV (n  514) VV (n  91) p Value
Total cholesterol (mg/dl) 220  44 220  46 225  49 0.4 218  45 223  46 225  48 0.13
LDL cholesterol (mg/dl) 141  38 142  41 144  45 0.7 141  40 143  40 145  45 0.5
HDL cholesterol (mg/dl) 46.3  13.5 48.3  15.8 49.9  13.7 0.015 46.9  14.5 48.3  14.8 50.0  16.3 0.09
Triglycerides (mg/dl) 168  110 168  110 169  104 0.9 171  120 168  99 154  88 0.4
Apolipoprotein A-I (g/l) 1.30  0.24 1.31  0.25 1.31  0.24 0.5 1.30  0.24 1.31  0.25 1.31  0.23 0.6
Apolipoprotein B-100 (g/l) 1.20  0.27 1.21  0.29 1.22  0.31 0.7 1.21  0.28 1.20  0.28 1.24  0.33 0.6
CETP activity (pmol/l/h) 40.7  20.3 36.8  21.8 31.8  16.3 0.0002 39.0  19.6 37.0  22.6 32.2  17.2 0.026
Data are presented as the mean value  SD. The p values were obtained by one-way analysis of variance. To convert values for cholesterol to millimoles per liter, multiply by
0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
Abbreviations as in Table 1.




















CC 444 75 (16.9) 48 (10.8) 16 (3.6) 11 (2.5) 15 (3.4) 63 (14.2)
CA 612 71 (11.6) 28 (4.6) 28 (4.6) 15 (2.5) 7 (1.1) 35 (5.7)
AA 150 17 (11.3) 6 (4.0) 6 (4.0) 5 (3.3) 3 (2.0) 9 (6.0)
p value 0.032 0.0001 0.7 0.8 0.045 0.0001
CETP/I405V
II 604 93 (15.4) 54 (8.9) 25 (4.1) 16 (2.7) 18 (2.8) 71 (11.8)
IV 512 58 (11.3) 28 (5.5) 18 (3.5) 12 (2.3) 6 (1.2) 34 (6.6)
VV 90 12 (13.3) 2 (2.2) 7 (7.8) 3 (3.3) 2 (2.2) 4 (4.4)
p value 0.14 0.023 0.18 0.8 0.15 0.006
*Including cardiovascular (CV) death, nonfatal myocardial infarction, and nonfatal stroke. †Including cardiovascular and noncardiovascular deaths. Data are presented as the
number (%) of subjects.
CETP  cholesteryl ester transfer protein.
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taking statin medication, whereas no difference was ob-
served in patients carrying the 629A allele (Table 5, Fig.
2). The same trend was observed with the CETP/I405V
polymorphism, but the interaction did not reach statistical
significance.
DISCUSSION
This prospective study, based on a large cohort of German
patients with documented CAD, confirmed that the CETP/
C-629A polymorphism influenced CETP activity and HDL
cholesterol levels and, more importantly, demonstrated, for
the first time, that the 629A allele was associated with a
strong protective effect on future cardiovascular mortality.
Despite heterogeneity in clinical presentation and patho-
physiology, this association was present in all subgroups
evaluated and remained highly significant even after con-
trolling for most potential confounders, including the strong
predictors of age and ejection fraction. Furthermore, the
CETP/C-629A polymorphism appeared to modulate the
long-term clinical benefit of statin therapy.
CETP was originally identified as a factor promoting the
transfer of cholesteryl esters from HDL to very-low-density
lipoprotein (VLDL) and LDL in exchange for triglycerides
(20,21). As a result of increasing VLDL/LDL cholesterol
concentrations and decreasing HDL cholesterol concentra-
tions, CETP has often been considered as being “pro-
atherogenic.” On the other hand, CETP is postulated to be
a direct (22) and indirect (5) mediator in RCT and should,
therefore, also be considered as “anti-atherogenic.”
An interesting window to elucidate the role of CETP in
atherosclerosis is provided by genetic studies. A common
TaqIB polymorphism located in intron 1 of the CETP gene
has been shown in several studies to be associated with
variations in CETP mass or activity and HDL cholesterol.
A protective effect of the B2 allele of this polymorphism on
the risk of CAD has been reported (10,23). Furthermore, in
the REgression GRowth Evaluation Statin Study
(REGRESS) clinical trial on pravastatin, the B2 allele was
reported to slow down the progression of coronary athero-
sclerosis in patients receiving a placebo, whereas no effect


















Model 1 1 0.40 0.34 0.0001 1 0.67 0.30 0.02
Age and gender — (0.25–0.64) (0.15–0.80) — (0.42–1.06) (0.07–1.22)
Model 2 1 0.42 0.37 0.001 1 0.68 0.31 0.03
Model 1 and HDL cholesterol — (0.26–0.67) (0.16–0.86) — (0.43–1.08) (0.08–1.28)
Model 3 1 0.37 0.49 0.009 1 0.70 0.46 0.15
Model 1 and CETP activity* — (0.20–0.70) (0.19–1.28) — (0.38–1.27) (0.11–1.93)
Model 4 1 0.42 0.39 0.002 1 0.69 0.43 0.09
Fully adjusted† — (0.25–0.73) (0.14–1.12) — (0.40–1.19) (0.10–1.82)
*Model 3 included only 865 patients for which CETP activity was measured. †Model 4 was adjusted for age, gender, body mass index, diabetes, hypertension, ever smoking,
HDL cholesterol, triglycerides, hs-CRP, acute coronary syndrome, extent of vessel disease, history of myocardial infarction, beta-blocker and statin therapy, 1 congestive heart
failure drug, CABG during follow-up, and ejection fraction (n  952 in model 4 due to 254 missing values for ejection fraction). The p values for trend were obtained by Cox
regression analysis, assuming a co-dominant effect of genotype. Data for CA and AA genotypes are presented as the hazard risk ratio (95% confidence interval).
Abbreviations as in Table 1.
Figure 1. Kaplan-Meier survival plots for cardiovascular mortality according to the cholesteryl ester transfer protein (CETP) polymorphisms.
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was observed in statin-treated patients (16). However, the
TaqIB polymorphism has no functional role by itself, and
other polymorphisms in linkage disequilibrium with it
should be responsible for the observed effects. A polymor-
phism at position 629 in the promoter of the CETP gene
was in nearly complete association with the TaqIB poly-
morphism. It was further shown that the 629A allele,
which is almost completely concordant with the B2 allele,
displayed a lower promoter activity than the 629C allele,
supporting the notion that this polymorphism might be
responsible, at least partly, for the effects initially observed
with the TaqIB polymorphism (14). In the present study,
the TaqIB polymorphism was also genotyped, but we did
not report the results because of the redundancy due to
strong linkage disequilibrium with the C-629A polymor-
phism. The effects of the CETP/I405V mutation on CETP
activity and HDL cholesterol were in accordance with
earlier studies (9,24,25). However, these effects appeared to
be mainly explained by its linkage disequilibrium with the
C-629A polymorphism. The two polymorphisms included
in the present study were selected on the basis of their
potential functionality, their relatively high frequency, and
their strong effects on HDL and CETP concentrations
(13). However, other polymorphisms might also be of
interest, in particular, two less frequent coding polymor-
phisms: A373P and R451Q. In the future, haplotype
analyses should be developed to evaluate the impact of all
CETP gene polymorphisms on prospective outcome.
In the present study, the mechanism relating CETP
genotype to cardiovascular risk appeared rather independent
of HDL cholesterol and CETP concentrations. However, it
should be stressed that the association of CETP genotype
with HDL cholesterol in this cohort of patients with CAD
was weaker than that generally reported in apparently
healthy subjects (9,10,24), and unlike previous studies, we
did not find any association with apolipoprotein A-I levels.
One explanation might be that lipid/lipoprotein levels in
this cohort of patients are not relevant intermediate pheno-
types because of modifications induced by treatment or
disease. It might also be speculated that the impact of
genotype on risk is rather mediated by a local effect of
CETP within the vessel wall.
One additional finding of our study was the interaction
between the CETP/C-629A polymorphism and statin ther-
apy on clinical outcome, with the beneficial effect of statin
therapy regarding future cardiovascular mortality being
restricted to CC homozygotes. Which putative mechanisms
might explain the relationship between the CETP/C-629A
polymorphism and long-term response to statin treatment?
The CC homozygotes have a stronger promoter activity and
exhibit the highest CETP expression level (14). Atorvasta-
tin, which was the most frequently prescribed statin in our
study, has been shown to decrease cholesteryl ester transport
from the protective HDL to the highly pro-atherogenic
VLDL subfraction and to decrease CETP activity (26).
This reduced cholesteryl ester transport from HDL to
VLDL, which appears as an important mechanism to lower
LDL cholesterol, might be enhanced in CC homozygotes,
explaining why these subjects benefit most from (atorva)sta-
tin therapy.
Some limitations of the present study must be stressed.
The AtheroGene study is not a prospectively randomized
statin-placebo trial. Moreover, we did not have the ability to
evaluate lipid parameters before and after statin therapy.
The results on the genotype-statin interaction should then
be considered as hypothesis-generating. Because we tested
several primary and secondary hypotheses that were not
independent, it was not possible to correct for multiple
testing; hence, the p values provided are nominal and








CC 40/305 (13.1%) 8/139 (5.8%) 0.02
CA 17/390 (4.4%) 11/222 (5.0%) 0.7
AA 3/100 (3.0%) 3/50 (6.0%) 0.4
p value for trend 0.0001 0.9
p value for heterogeneity 0.01
CETP  cholesteryl ester transfer protein.
Figure 2. Hazard risk ratios of future cardiovascular death according to the
cholesteryl ester transfer protein (CETP)/C-629A polymorphism and statin
therapy.
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require further confirmation. Another limitation of the
study is the relatively low number of events. Therefore, it is
important to replicate these results in other prospective
studies. Finally, the issue of whether or not the genotype
effect is mediated by modifications of circulating lipid
concentrations requires further evaluation.
Conclusions. This study demonstrated, for the first time,
the strong protective effect of the CETP/629A allele on
the risk of future mortality from cardiovascular causes in
patients with CAD. Our data further suggested that this
genetic marker may help to identify those patients who
would most likely achieve a clinical benefit from statin
therapy.
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